Last edition
News about
Noramco Launches Noramco Group to Strengthen North American Pharmaceutical Supply Chain
This initiative integrates subsidiaries Purisys, Noramco, and recently acquired drug product CDMO, Halo Pharma, to enhance the region's clinical and commercial API and drug product supply chain.
Aptar Expands North American Capacity to Meet Growing Demand for Drug Delivery Systems
This investment aims to address the increasing demand for proprietary drug delivery systems in both prescription and consumer healthcare markets across North America, benefiting local customers.
BeiGene Receives FDA Approval for TEVIMBRA
BeiGene announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA ® (tislelizumab) as a treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously received unresectable or metastatic esophageal squamous cell carcinoma (ESCC).
Biotheus will grant Hansoh Pharma a license to use the proprietary anti-EGFR/cMet bispecific antibody PM1080/HS-20117 independently developed by Biotheus for the development of antibody-drug conjugates products (ADC Product).
Chronic sinusitis, affecting around 30 million adults in the United States, is a prevalent chronic condition that significantly impacts patients' quality of life.
Bioretec Receives FDA Breakthrough Device Designation for RemeOs Spinal Interbody Cage Implant
The RemeOs Spinal Interbody Cages, designed to restore intervertebral height and facilitate intervertebral body fusion in the cervical spine, are poised to revolutionize treatment options for patients with spinal conditions.
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
Vapotherm, Inc. announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.
Cardinal Health Announces Approved Science-Based Climate Targets; Expands Focus Across Supply Chain
Cardinal Health announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets.
FDA Approves Rezdiffra (resmetirom) for Treatment of NASH with Liver Scarring
NASH, a consequence of nonalcoholic fatty liver disease, can lead to liver inflammation and scarring over time, resulting in liver dysfunction.
CPHI Japan 2024 to See More Than 20 percent Year-on-Year Rise
The event is widely seen as a barometer of overall health in the country’s pharma industry and in light of significant R&D growth, Tides will collaborate with CPHI Japan to introduce a free conference.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy